INTRODUCTION {#sec1}
============

Diabetes mellitus (DM) is one of chronic conditions, requiring continual comprehensive management to reduce the risk of complications and cardiovascular diseases. National diabetes programmes are build in many countries to organize the accessibility and quality of diabetes care. Lithuania is amongst those countries, where no national diabetes programme is implemented. With a population of approximately 3 million residents, the prevalence of diabetes in Lithuania was 4.9% in 2013 according to the International Diabetes Federation and 3.9% according to the Institute of Hygiene Health Information Centre under the Ministry of Health of the Republic of Lithuania ([@ref1], [@ref2]). The discrepancy of epidemiological data and the lack of current quality of diabetes care analysis is an important missing part for the National Diabetes Programme, which is currently under development. Data from the Diabetes Experts Panel from Accessing Countries (DEPAC) study showed the average glycated haemoglobin (HbA1c) of 8.45% in type 1 DM (T1DM) and 7.77% in type 2 DM (T2DM) subjects in Lithuania in 2005 ([@ref3]). The other study at the primary care level showed that the target HbA1c of \<7% was achieved in 51% of patients in 2007--2008 ([@ref4]). Both studies included a randomly selected small number of subjects and covered only some aspects of diabetes care. Recently we have published the data of the comprehensive diabetes care audit, performed at the Vilnius University Hospital Santariškių Klinikos (Santariskiu Clinics) Centre of Family Medicine, where the quality of diabetes care was assessed against the local Diabetes Care Guidelines, using the process and outcome indicators in a sample of 315 patients. The average HbA1c was 6.9% and the proportion of patients reaching the target \<7% was 67%, however, patients education, continuous monitoring for complications and cardiovascular risk factors did not meet the local guidelines ([@ref5]). These data showed that the current guidelines did not secure performance of the described procedures for assessment of diabetes complications and encouraged to expand our research to other Vilnius outpatient clinics in a representative sample of patients.

The aim of our study was to assess the quality of diabetes care against the local Diabetes Care Guidelines and to identify the weakest links in order to address them in the National Diabetes Programme, which is currently being developed.

MATERIALS AND METHODS {#sec2}
=====================

**Setting.** Diabetes management was assessed in the 5 largest public outpatient clinics of Vilnius -- the capital of Lithuania with over 500 thousands of inhabitants and 3.25% incidence of diabetes in 2013 for adults above 18 years. Each primary outpatient clinic serves about 60,000 residents. Diabetes care is provided by primary care physicians, diabetes nurses and specialists.

**Local Diabetes Care Guidelines.** According to the described procedures, HbA1c has to be evaluated every 3 months in all patients with diabetes. General practitioners have to refer patients to an endocrinologist if HbA1c\<7% is not reached in 6 months or evaluation for diabetes complications is needed. Diabetes complications and cardiovascular risk factors have to be assessed annually.

**Preparation.** The study was approved by the Vilnius Regional Bioethics Committee on 11 of February 2014. A standardized data collection form, covering the aspects described in the local Diabetes Care Guidelines, was prepared. One or two researchers, responsible for data collection, were recruited in each clinic. Training workshops were held prior to data collection and later during the process to ensure the quality of data collection.

**Sample size and data management.** The sample size calculation based on the total number of people, registered with each clinic, the proportion of adults and the percentage of patients with diabetes was done. The total sample size calculated was 1,675 for the 95% confidence level and 5% precision. Systematic random sampling was conducted in the five outpatient clinics. The sampling interval (k) was set according to the number of adults registered with each clinic and the required sample size. A random number was selected between 1 and k. Every kth patient was selected starting from that random number. Data collection was conducted in 3 months (May to July 2014) and covered the period from 2012 until 2013 (inclusive). An electronic database system was used in each clinic to extract data of all adult patients, who had diagnostic codes of type 1 or type 2 diabetes -- E10.0--E10.9 or E11.0--E11.9 according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM). The list of patients was used to randomly select the estimated number of subjects for evaluation.

Data was collected from the clinical notes and the electronic database system into a standardized data collection form. The sampled patients qualified for the review if they: 1) had been attending the clinic for at least 1 year; 2) had diabetes diagnosed for at least 12 months.

The following data was collected:

-   Demographic: year of birth, gender, type of diabetes, year of diabetes diagnosis.

-   Current glucose lowering therapy.

-   Process indicators of the quality of diabetes care:

    -   Physical examination: body weight, body mass index (BMI), blood pressure (BP).

    -   Annual performance of plasma creatinine, urine albumin/creatinine ratio or daily microalbuminuria, lipid profile, retinal screening, feet examination.

    -   HbA1c performance rate.

-   Outcome indicators of the quality of diabetes care:

    -   Glycaemia control.

    -   Referral rate to an endocrinologist.

    -   BP control.

    -   Diabetes complications if they are present in diagnosis or:

        -   Retinopathy, diagnosed by an ophthalmologist through retinal screening.

        -   Nephropathy, diagnosed by nephrologists or albumin/creatinine ratio or daily microalbuminuria testing.

        -   Neuropathy, diagnosed by a neurologist or feet examination.

        -   Angiopathy, diagnosed by an angiosurgeon.

Lipid control was not used as an outcome indicator due to a very low lipid profile assessment rate.

If data was not found in the clinical notes or the electronic database system, it was considered missing.

**Statistical analysis.** Statistical analysis was performed with the IBM Statistical Package for the Social Sciences version 19.0 and MS Excel 2010. The results were presented as average ± standard deviation (SD) for continuous variables and as absolute numbers and percentages for categorical variables. The data was checked for normality using the Shapiro--Wilk test. Continuous variables between the groups were compared by the Mann--Whitney U-test (2 groups) and by the Kruskal--Wallis test (\>2 groups). Categorical variables were analyzed with the χ2 test or Fisher's exact test. All *p* values were two-tailed and the level of significance was set to 0.05.

RESULTS {#sec3}
=======

Patient characteristics {#sec3_1}
-----------------------

There were 1,729 out of 14,363 patients with diabetes selected and included into the analysis -- 128 with T1DM and 1,591 with T2DM. The type 2 diabetes subjects were elder, more obese, had a shorter diabetes duration and a higher proportion of women ([Table 1](#T1){ref-type="table"}).

Diabetes treatment strategy {#sec3_2}
---------------------------

The highest proportion of T2DM patients -- 71.9% were treated with oral antidiabetic agents; 58.7% of them were on metformin monotherapy, 24.1% on combination of metformin and sulphonilurea, 10% on sulphonilurea monotherapy. Dipeptidyl peptidase- 4 inhibitors and pioglitazon were administered in combination with other antidiabetic agents for 4.6 and 2.6% of the patients, respectively. Only 0.7% of T2DM patients were treated with glucagon-like peptide-1 receptor agonists. Combination of insulin therapy and oral agents was used in 9.5% of patients, insulin therapy in 11.2%. There were 6.7% of the T2DM subjects controlled with a diet only.

Process indicators of the quality of diabetes care {#sec3_3}
--------------------------------------------------

Body weight and BMI were measured and recorded for about 50% of the subjects, blood pressure in more than 95% in both groups. Adherence to the recommendations for annual check of diabetes related parameters and complications was assessed calculating the number of examinations performed within 2 years. There was a clear tendency of a higher number of screenings performed in a longer period of time: for example, there were 32% of the T1DM and 23.8% of the T2DM subjects assessed for retinopathy annually for 2 consecutive years, but this number increased to 43.8 and 36.6%, respectively, who had screening ones in 2 years. However, there were still 24.2% of the T1DM and 39.7% of the T2DM subjects who were not referred for retinal screening at all in a 2-year period ([Table 2](#T2){ref-type="table"}). Poor adherence to the local guidelines was noticed for other diabetes related parameters: plasma creatinine was performed annually in 29.3%, lipid profile in 13.2%, feet examination in 4.6% of the subjects without difference between the groups ([Table 2](#T2){ref-type="table"}). The type 1 DM patients were more frequently screened for diabetic nephropathy annually -- 10.9% vs 1.6% (*p* \< 0.001) and retinopathy 32% vs 23.8% (*p* = 0.002) compared to the T2DM. The proportion of the patients for whom diabetes related parameters were not assessed at all in 2 years was very high: 80.1% for feet examination, 38.5% for retinal screening, 60% for lipid profile, 83.0% for urinary microalbuminuria and 27.4% for plasma creatinine with difference in the T1DM and T2DM groups only for retinal screening and microalbumin assessment ([Table 2](#T2){ref-type="table"}). There were only 3.3% of the subjects who underwent a complete check for all diabetes related parameters annually.

###### 

Basic characteristics of the group

                                                                         All (N = 1719)   T1DM (N = 128)   T2DM (N = 1591)   *P* value
  ------------------------------------------------------ --------------- ---------------- ---------------- ----------------- -----------
  Gender                                                 Men             707 (41.1%)      64 (50%)         643 (40.4%)       0.034
  Women                                                  1012 (58.9%)    64 (50%)         948 (59.6%)                        
  Age, years                                             64.16 ± 13.38   40.04 ± 13.13    66.10 ± 11.37    \<0.001           
  Diabetes duration, years[\*](#tfn1_1){ref-type="fn"}   8.18 ± 6.94     16.82 ± 11.49    7.49 ± 5.92      \<0.001           
  BMI, kg/m^2^[\*\*](#tfn1_2){ref-type="fn"}             31.94 ± 6.22    23.79 ± 3.74     32.68 ± 5.86     \<0.001           
  BMI ≥ 30 kg/m^2^, %[\*\*](#tfn1_2){ref-type="fn"}      559 (64.8)      5 (6.9)          554 (70.0)       \<0.001           
  SBP \< 130 mmHg, %[\*\*\*](#tfn1_3){ref-type="fn"}     651 (39.0)      84 (68.9)        567 (36.6)       \<0.001           
  DBP \< 80 mmHg, %[\*\*\*](#tfn1_3){ref-type="fn"}      998 (59.7)      86 (70.5)        912 (58.9)       0.005             
  Diabetes complications, N (%)                                                                                              
  Polyneuropathy                                         622 (36.2)      89 (69.5)        533 (33.5)       \<0.001           
  Retinopathy                                            184 (10.7)      64 (50.0)        120 (7.5)        \<0.001           
  Nephropathy                                            144 (8.4)       27 (21.1)        117 (7.4)        \<0.001           
  Angiopathy                                             133 (7.7)       17 (13.3)        116 (7.3)        0.015             

\* Missing: total 152, T1DM 12, T2DM 140.

\*\* Missing: total 856, T1DM 56, T2DM 800.

\*\*\* Missing: total 48, T1DM 6, T2DM 42.

*P* value compares T1DM and T2DM groups.

The estimated HbA1c assessment rate reached 88.6% at least once a year and was one of the highest among other annual checks. There was a significantly higher frequency of the HbA1c measurement in the well controlled T1DM subjects (HbA1c \< 7%), compared to that of the T2DM patients (*p* = 0.024), however, such a difference disappeared in other groups irrespectively of the HbA1c value ([Table 3](#T3){ref-type="table"}). The recommended frequency of the HbA1c measurement every 3 months was achieved only in 2.4% of the T1DM and 3% of the T2DM subjects. The best estimated performance was for measuring and recording blood pressure -- 95.3 and 97.4% in T1DM and T2DM, respectively.

There were no difference in adherence to the local guidelines in 2012 and 2013.

Outcome indicators of the quality of diabetes care {#sec3_4}
--------------------------------------------------

The average HbA1c of the total sample was 7.2 ± 1.5% with a significant difference between the groups -- 9.1 ± 1.8% in T1DM vs 7.0 ± 1.4% in T2DM (*p* \< 0.05). The target HbA1c of \<7% was achieved in 55.3% of cases: in 9.4% of the T1DM and in 59.0% of the T2DM subjects. Within the T2DM group the lowest HbA1c was estimated in the patients treated with diet and the highest HbA1c was in the group of combined treatment with insulin and oral medications ([Figure](#fig1){ref-type="fig"}). There was a clear relation between HbA1c and diabetes complications: the more complications the higher HbA1c both in the T1DM and T2DM subjects ([Table 4](#T4){ref-type="table"}). Worsening of HbA1c with diabetes duration was observed in the T2DM subjects with the worst results in the patients with disease lasting for 16--20 years. Contrary, in the T1DM the worst HbA1c was estimated at the first five years and then after 16--20 years of disease ([Table 4](#T4){ref-type="table"}).

Despite a relatively low proportion of subjects reaching the target HbA1c, only 56.3% of needful referrals to an endocrinologist were performed, as recommended by the local guidelines. Theoretically patients with HbA1c ≥ 7% have to consult a specialist each six months, however, the average referral rate in the T2DM subjects did not reach even one visit per year. A similar situation was observed in the T1DM, except of the patients with HbA1c between ≥ 8 and \<9%, who consulted an endocrinologist once a year. There was a tendency of more frequent referral with worsening of HbA1c in T2DM, but not T1DM ([Table 3](#T3){ref-type="table"}).

###### 

Annual checks for diabetes related parameters

  Measure                                                           Recorded N,%   *P* value     
  ----------------------------------------------------------------- -------------- ------------- -------
  Weight                                                            75 (58.6)      879 (55.3)    0.464
  BMI                                                               72 (56.3)      791 (49.7)    0.155
  Blood pressure                                                    122 (95.3)     1549 (97.4)   0.165
  Feet examination[\*](#tfn2_1){ref-type="fn"}                                                   0.509
  1                                                                 24 (18.8)      239 (15.0)    
  2                                                                 5 (3.9)        74 (4.7)      
  Retinal screening (ophthalmologist)[\*](#tfn2_1){ref-type="fn"}                                0.002
  0                                                                 31 (24.2)      631 (39.7)    
  1                                                                 56 (43.8)      582 (36.6)    
  2                                                                 41 (32)        378 (23.8)    
  Lipid profile[\*](#tfn2_1){ref-type="fn"}                                                      0.804
  0                                                                 80(62.5)       950 (59.7)    
  1                                                                 33 (25.8)      430 (27)      
  2                                                                 15 (11.7)      211 (13.3)    
  Plasma creatinine[\*](#tfn2_1){ref-type="fn"}                                                  0.305
  0                                                                 29 (22.7)      442 (27.8)    0
  1                                                                 55 (43)        690 (43.4)    
  2                                                                 44 (34.4)      459 (28.8)    
  Urinary microal-buminuria[\*](#tfn2_1){ref-type="fn"}                            \<0.001       
  0                                                                 62 (48.4)      1365 (85.8)   0
  1                                                                 52 (40.6)      201 (12.6)    
  2                                                                 14 (10.9)      25 (1.6)      

\* Number of examinations within 2 years.

###### 

HbA1c assessment and referral to an endocrinologist

  HbA1c, %                                                                               All (N = 1643)          T1DM (N = 123)         T2DM (N = 1520)         *P* value
  -------------------------------------------------------------------------------------- ----------------------- ---------------------- ----------------------- -----------
  HbA1c assessment rate (times/2 years)                                                                                                                         
  \<7                                                                                    4.1 ± 1.80 (N = 950)    5.25 ± 1.60 (W = 12)   4.08 ± 1.80 (N =938)    0.024
  ≥7-- \<8                                                                               4.22 ± 1.85 (N = 316)   3.85 ± 1.94 (N = 27)   4.25 ± 1.85 (N = 289)   0.347
  ≥8 -- \<9                                                                              4.31 ± 1.77 (N = 169)   4.46 ± 1.90 (N = 28)   4.28 ± 1.75 (N = 141)   0.575
  ≥9                                                                                     3.75 ± 1.83 (N = 208)   3.70 ± 1.72 (N = 56)   3.76 ± 1.87 (N = 152)   0.958
  **Referral rate to an endocrinologist (times/2 years) [\*](#tfn3_1){ref-type="fn"}**                                                                          
  \<7                                                                                    0.65 ± 0.93             0.75 ±0.75             0.65 ± 0.93             0.393
  ≥7-- \<8                                                                               1.27 ± 1.17             1.15 ± 1.17            1.28 ± 1.18             0.553
  ≥8 -- \<9                                                                              1.57 ± 1.62             2.32 ± 1.94            1.43 ± 1.51             0.020
  ≥9                                                                                     1.66 ± 1.46             1.48 ± 1.64            1.72 ± 1.38             0.093

\* Number of patients in different HbA1c groups is the same as in the above part of the table.

![Difference in HbA1c depending on treatment strategy in the type 2 diabetes subjects group](aml-23-126-g001){#fig1}

###### 

Glycemic control in relation to the diabetes duration and number of complications in the T1DM and T2DM subjects

  Diabetes duration, years      HbA1c, %               
  ----------------------------- ---------------------- -----------------------
  **0--5**                      9.46 ± 2.03 (N=19)     6.25 ± 2.05 (N = 682)
  **6--10**                     8.60 ± 1.42 (N=18)     7.17 ± 1.39 (N = 395)
  **11--15**                    8.39 ± 3.99 (N=24)     7.27 ± 232 (N=257)
  **16--20**                    9.75 ± 1.85 (N=17)     7.50 ± 1.92 (N=73)
  **\>20**                      8.83 ± 1.68 (N=38)     7.44 ± 1.23 (N = 44)
  **Number of complications**   **T1DM (N = 120)**     **T2DM (N= 1517)**
  **0**                         8.84 ± 1.93 (N=22)     6.72 ± 1.13 (N=882)
  **1**                         8.94 ± 1.71 (N=37)     7.30 ± 1.5 (N = 457)
  **2**                         9.29 ± 1.54 (N = 40)   7.63 ±1.51 (N=140)
  **3**                         9.4 2 ± 2.16 (N=21)    8.66 ± 1.94 (N=38)

The evaluation of BP control was based on the proportion of subjects with the goal of SBP \< 130 mmHg and DBP \< 80 mmHg achieved. There were about 70% of the T1DM subjects with BP well controlled, compared to 36.6% for the systolic BP (*p* \< 0.001) and 58.9% for the diastolic BP (*p* = 0.005) target reached in the T2DM group ([Table 1](#T1){ref-type="table"}).

The most prevalent diabetes complication was polyneuropathy estimated in more than a third of all subjects, reaching 69.5% and being twice more frequent in the T1DM compared to 33.5% in the T2DM group (*p* \< 0.001). Overall, all complications were more prevalent in the T1DM patients, with retinopathy affecting half, nephropathy 21.1% and angiopathy 13.3% of the subjects, compared to 7.5, 7.4 and 7.3% in the T2DM group, respectively (*p* \< 0.001) ([Table 1](#T1){ref-type="table"}).

DISCUSSION {#sec4}
==========

Our study analysed the quality of diabetes care against the local Diabetes Care Guidelines in the five largest Vilnius outpatient clinics. This is the first comprehensive situation analysis in Lithuania in a representative sample of 1,729 diabetes subjects at the institutions providing primary health care for 441,198 patients, i. e. 69% of the residents of Vilnius area. Information on the current achievement in diabetes care provides directions for National Diabetes Programme development. The main characteristics of our patients were similar to those investigated in comparable studies carried out in Europe (6--10). Patients with T2DM accounted for 93% of the sample, were by 25 years senior and more obese, and had a twice shorter disease duration than those with T1DM.

Our data revealed very good results of annual HbA1c testing, which has reached 88.6%. In comparison, annual HbA1c testing rates were 45% in Luxembourg, 56--58% in Spain, 64--75% in New Zealand and Australia, 68.4% in Finland, 74% in Bosnia and Herzegovina, 86.2% in Estonia, 91% in Germany, 92% in UK, 92--93.5% in Italy ([@ref7], [@ref11]--[@ref18]). Relatively better performance of this process indicator in our study can be explained by the incentive payment for HbA1c testing which was implemented in the Lithuanian Health Care System since 2006. However, a recent study of Suija et al. revealed that the optimal HbA1c testing rate does not necessarily warrants better glycaemia control ([@ref14]). The data from four European countries -- Estonia, Finland, Lithuania and Spain -- revealed that Lithuania was the leading country for the annual performance of HbA1c (90.6% vs 57.7--86.2%), however, the proportion of patients achieving the target HbA1c ≤ 7% was the lowest compared to those of other countries (49.7 vs 61.9--67.7%) ([@ref14]). The frequency of HbA1c measurement in our study was almost the same irrespectively of the result. One could anticipate a higher performance rate in poorly controlled subjects that would be an indirect indicator of close monitoring and efforts to adjust treatment.

The related outcome indictor -- estimated average HbA1c -- was 7.2% in our sample and was higher than the one revealed in the outpatient clinic of Vilnius University Hospital Santariškių Klinikos (Santariskiu Clinics) -- 6.9%, but better in comparison to reported 7.4% in several primary care centres in Lithuania ([@ref4], [@ref5]). The average HbA1c in the T2DM was significantly better compared to that in the T1DM group -- 7.0% vs 9.1%. The results of studies, conducted in T2DM subjects, showed an average HbA1c of 7.5% in Estonia, 6.8--7.2% in Spain, 6.7% in Germany, 7.0% in Greece, 7.1% in Belgium ([@ref9]--[@ref12], [@ref17], [@ref19]). Our study revealed a very poor glycaemic control in the T1DM which, however, is in line with the meta-analysis of the registers of 11 countries published by McKnight et al., where the median HbA1c in the T1DM varied from 7.4 to 9.4% ([@ref20]). Similar data were revealed by the Swedish National Diabetes Register, where an average HbA1c of 8% in the T1DM population was estimated ([@ref21]).

The estimated worsening of diabetes control with an increasing number of complications, disease duration and intensification of treatment, same as a worse glycaemic control in the patients treated with insulin compared to oral therapy users in the T2DM group, agrees with the previously published data ([@ref10], [@ref12], [@ref19]).

Our data showed that 55.3% of patients achieved HbA1c \< 7% which is worse than the average result in other European countries -- 62.6%, reported in the Panorama study ([@ref22]), but falls in between countries, where the percentage of T2DM patients reaching the target HbA1c ≤ 7 varies from 48.1 to 76.0% ([@ref10], [@ref12], [@ref19], [@ref21], [@ref23]).

Only 56% of the patients with HbA1c of ≥7% were referred to an endocrinologist which confirms that even when HbA1c is measured, this not always leads to an adequate action taken. And although this study was not designed to assess clinical inertia, a low referral rate irrespectively of a poor HbA1c and increasing HbA1c with a more complex therapy are indirect indicators of such situation.

The frequency of annual checks for diabetes complications showed a poor compliance to the Diabetes Care Guidelines, with the worst performance for urinary microalbumin, especially in the T2DM patients. This may be due to a relatively high cost of this analysis. There was also a clear disagreement between the complications diagnosed and the care provided: for example, diabetic polyneuropathy and angiopathy were estimated in 69.5 and 13.3% of T1DM and 33.5 and 7.3% of T2DM patients, but an annual foot examination was performed only in 3.9 and 4.7% of patients, respectively. Even a simple check such as a BW measurement showed a very poor performance, suggesting an insufficient attention for routine care measures. An insufficient performance of annual checks was also recorded in other countries: performance for BMI varied from 25 to 91%, BP from 67 to 99%, retinal screening from 28 to 58%, plasma creatinine from 27 to 92.5%, urinary microalbuminuria or albumin-creatinin ratio from 24 to 74%, foot examination from 33 to 85% in different studies ([@ref7]--[@ref9], [@ref15], [@ref16], [@ref18], [@ref20], [@ref22], [@ref24], [@ref25]). The highest performance of annual checks was reported in UK, where annual national diabetes audits are performed ([@ref15]).

The most prevalent complication in our study was diabetic polyneuropathy, estimated in more than a third of patients and more than three times prevalent compared to other complications in the T2DM group. This may be related to the fact that symptomatic treatment of neuropathic pain is reimbursed only in case the diagnosis of diabetic neuropathy is present. Data of other studies vary, showing almost equal 10--12% prevalence of microvascular complications reported by Goderis et al. in Belgium, 30--40% rate for retinopathy, 25--28% for nephropathy and about 31% for neuropathy in the T1DM and T2DM subjects in the DEPAC study with noticeable differences between countries ([@ref6], [@ref10]).

Limitations of the study {#sec4_1}
------------------------

Our study represents only the biggest Vilnius public outpatient clinics. Private and small public primary health care institutions were not involved in the study. Such smaller centres take care of about 31% of Vilnius city inhabitants. Also, we do not represent smaller cities and rural areas, where availability of health care resources might be even more limited. This definitely needs further research, which is under development.

In order to assess the long-term diabetes control we were using the threshold of HbA1c \< 7%, which is recommended by the local guidelines and is easy to understand and simple to report. However, in the light of recent clinical trial results and subsequent guideline recommendations to individualize clinical goals for HbA1c, selection of an appropriate threshold becomes difficult. Thus the interpretation of current results, if an individualised approach is used, might look in some way different.

CONCLUSIONS {#sec5}
===========

The analysis of quality of diabetes care at the five largest Vilnius outpatient clinics revealed satisfactory glycaemic control, but poor management of diabetes complications and cardiovascular risk factors. These results put new information and, although the data are regional, when combined with a few previously conducted studies, confirms the weakest links of diabetes care in Lithuania and indicates the direction for improvement. Implementation of quality control procedures, continuous monitoring of the relation between process and outcome indicators, development of the diabetes patients register and electronic database, implementation of the personalized diabetes care approach need to be addressed in the National Diabetes Programme.
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